Treating Tinea Pedis In Patients With Diabetes

Lisa Matricciani, RN, and Sara Jones, PhD, MSc, BA, DipAppSci

1. Thomas J, et al. Tinea pedis and onychomycosis are contagious fungal infections that affect the feet and toenails (respectively) of approximately 15-20% of the population. J Clin Pharm Ther. 2010. 35(5):497-519.
2. Schlefman B. Onychomycosis: a compendium of facts and a clinical experience. J Foot Ankle Surg. 1999; 38(4):290-302.
3. Elewski B, Hay R. Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin Infec Dis. 1996; 23(2):305-313.
4. Gupta A, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol. 1998; 139(4):665-671.
5. Armstrong D, Holtz K, Wu S. Can the use of a topical antifungal nail lacquer reduce risk for diabetic foot ulceration? Results from a randomised controlled pilot study. International Wound J. 2005; 2(2):166-170.
6. Cox N, Colver G, Paterson W. Management and morbidity of cellulitis of the leg. J Royal Society Medicine. 1998; 91(12):634-637.
7. Pierce R, Daugird A. Recurrent leg cellulitis: pathogenesis, prevention and treatment. J Amer Board Family Med. 1992; 5(1):85-87.
8. Brodell J, Brodell R. Recurrent lymphangitic ellulitis syndrome. Contemporary Orthopaedics. 1992; 25(5):461-468.
9. Rich P. Special patient populations: onychomycosis in the diabetic patient. J Am Acad Dermatol. 1996; 35(3):s10-s12.
10. Pomposelli JJ, Baxter JK 3rd, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. J Parenter Enteral Nutr. 1998; 22(2):77-81.
11. Anarella J, Toth C, Debello J. Preventing complications in the diabetic patient with toenail onychomycosis. J Amer Podiatr Med Assoc. 2001; 91(6):325-328.
12. Doyle J, Boyko WL, Ryu S, et al. Onychomycosis among diabetic patients: prevalence and impact of nonfungal foor infection. Presented at American Diabetes Association 60th Scientific Sessions; June 9-13, 2000; San Antonio, TX.
13. Boyko E, Ahroni JH, Cohen V, Nelson KM, Heagerty PJ. Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle diabetic foot study. Diabetes Care. 2006; 29(6):1202-1207.
14. Bell-Syer S, Hart R, Crawford F, et al. Oral treatments for fungal infections of the skin of the foot. Cochrane Database of Systematic Reviews 2002(2):CD003584.
15. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database of Systematic Reviews. 2007; 18(3):CD001434.
16. Tan J, Joseph WS. Common fungal infections of the feet in patients with diabetes mellitus. Drugs Aging. 2004; 21(2):101-112.
17. Grant R, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003; 26(5):1408-1412.
18. Venkatakrishnan K, Von Moltke L, Greenblatt D. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clinical Pharmacokinetics. 2000; 38(2):111-180.
19. Verspeelt J, Marynissen J, Gupta AK, De Doncker P. Safety of itraconazole in diabetic patients. Dermatology. 1999; 198(4):382-384.
20. Gupta A, Gover M, Lynde C. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. J Eur Acad Dermatol Venereol. 2006; 20(10):1188-1193.
21. Gupta A, Katz I, Shear N. Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J Amer Acad Dermatol. 1999; 41(2):237-249.
22. Grant S, Clissold S. Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989; 37(3):310-344.
23. Baran R, Hay RJ, Garduno JI. Review of antifungal therapy and the severity index for assessing onychomycosis: Part I. J Dermatol Treat. 2008; 19(2):72-81.
24. Vickers A, Sinclair JR, Zollinger M, et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug–drug interactions. Drug Metabolism Dispos. 1999; 27(9):1029-1038.

Add new comment